Table 5 Association of TIER1 hotspot mutations with precancers and cancers by HPV type/groups among samples collected within 2 years of outcome ascertainment

From: Somatic mutations in 3929 HPV positive cervical cells associated with infection outcome and HPV type

HPV type/group

Status

Total

No HS mutation

HS mutations

P

OR

95%CI

N

%

N, ≥ 1 HS

%

   

HPV16

Control

665

645

97.0%

20

3.0%

ref

   
 

CIN2

244

238

97.5%

6

2.5%

0.66

0.81

0.32

2.05

 

CIN3/AIS

844

798

94.5%

46

5.5%

0.02

1.86

1.09

3.17

 

CIN3

750

714

95.2%

36

4.8%

0.09

1.63

0.93

2.84

 

AIS

94

84

89.4%

10

10.6%

8.8 × 10−4

3.84

1.74

8.48

 

Cancer

103

75

72.8%

28

27.2%

4.2 × 10−15

12.04

6.47

22.42

 

SCC

50

31

62.0%

19

38.0%

6.7 × 10−16

19.77

9.58

40.77

 

ADC

43

35

81.4%

8

18.6%

1.0 × 10−5

7.37

3.03

17.91

   

N

%

N,PIK3CA

%

    
 

Control

648

645

99.5%

3

0.5%

ref

   
 

Cancer

93

75

80.6%

18

19.4%

5.4 × 10−10

51.60

14.85

179.28

 

SCC

42

31

73.8%

11

26.2%

1.5 × 10−10

76.36

20.25

287.85

 

ADC

41

35

85.4%

6

14.6%

7.3 × 10−7

36.90

8.85

153.81

   

N

%

N, non-PIK3CA

%

    
 

Control

659

645

97.9%

14

2.1%

ref

   
 

Cancer

83

75

90.4%

8

9.6%

5.3 × 10−4

4.91

2.00

12.10

 

SCC

37

31

83.8%

6

16.2%

2.7 × 10−5

8.92

3.21

24.78

 

ADC

37

35

94.6%

2

5.4%

0.21

2.63

0.58

12.04

HPV18/45

  

N

%

N, ≥ 1 HS

%

    
 

Control

557

543

97.5%

14

2.5%

Ref

   
 

CIN2

210

204

97.1%

6

2.9%

0.79

1.14

0.43

3.01

 

CIN3/AIS

159

154

96.9%

5

3.1%

0.66

1.26

0.45

3.55

 

CIN3

108

107

99.1%

1

0.9%

0.33

0.36

0.05

2.79

 

AIS

50

46

92.0%

4

8.0%

0.04

3.37

1.07

10.67

 

Cancer

38

30

78.9%

8

21.1%

1.2 × 10−6

10.34

4.03

26.56

 

SCC

10

9

90.0%

1

10.0%

0.18

4.31

0.51

36.37

 

ADC

27

20

74.1%

7

25.9%

4.3 × 10−7

13.57

4.94

37.31

   

N

%

N,PIK3CA

%

    
 

Control

547

543

99.3%

4

0.7%

ref

   
 

Cancer

34

30

88.2%

4

11.8%

7.4 × 10−5

18.14

4.32

76.07

 

SCC

10

9

90.0%

1

10.0%

0.02

15.12

1.54

148.95

 

ADC

23

20

87.0%

3

13.0%

1.5 × 10−4

20.39

4.28

97.24

   

N

%

N, non-PIK3CA

%

    
 

Control

553

543

98.2%

10

1.8%

ref

   
 

Cancer

34

30

88.2%

4

11.8%

1.4 × 10−3

7.24

2.15

24.44

 

SCC

9

9

100.0%

0

0.0%

0.93

-

-

-

 

ADC

24

20

83.3%

4

16.7%

1.7 × 10−4

10.87

3.14

37.66

  1. CIN2 cervical intraepithelial neoplasia grade 2, CIN3 CIN grade 3, AIS adenocarcinoma in situ, SCC squamous cell carcinoma, ADC adenocarcinoma. Samples with co-occurrence of both PIK3CA and non-PIK3CA mutations were excluded from the analyses. HS hotspot; P = multinomial logistic regression, OR odds ratio, Cl confidence interval. Significant P-values are bolded. OR, 95%CI, and P-values were estimated using multinomial logistic regression; tests were two-sided.
Back to article page